Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-090746
Filing Date
2024-08-05
Accepted
2024-08-05 16:10:26
Documents
58
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q crsp-20240630.htm   iXBRL 10-Q 1692676
2 EX-10.2 crsp-ex10_2.htm EX-10.2 146038
3 EX-31.1 crsp-ex31_1.htm EX-31.1 11420
4 EX-31.2 crsp-ex31_2.htm EX-31.2 11420
5 EX-32.1 crsp-ex32_1.htm EX-32.1 10117
  Complete submission text file 0000950170-24-090746.txt   7041145

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT crsp-20240630.xsd EX-101.SCH 890587
61 EXTRACTED XBRL INSTANCE DOCUMENT crsp-20240630_htm.xml XML 1294318
Mailing Address BAARERSTRASSE 14 ZUG V8 CH-6300
Business Address BAARERSTRASSE 14 ZUG V8 CH-6300 6173154600
CRISPR Therapeutics AG (Filer) CIK: 0001674416 (see all company filings)

EIN.: 473173478 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37923 | Film No.: 241174845
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)